Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8

Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8

Abstract Background Paclitaxel (PTX) is a potent anti-cancer drug commonly used for the treatment of advanced breast cancer (BCA) and melanoma. Toll-like receptor 4 (TLR4) promotes the production of pro-inflammatory cytokines associated with cancer chemoresistance. This study aims to explore the eff...

Full description

Bibliographic Details
Main Authors: Rochanawan Sootichote, Peti Thuwajit, Ekapot Singsuksawat, Malee Warnnissorn, Pa-thai Yenchitsomanus, Suthinee Ithimakin, Jomjit Chantharasamee, Chanitra Thuwajit
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
TLR4
Paclitaxel
Breast cancer
Melanoma
Tumor microenvironment
Compound A
Online Access:http://link.springer.com/article/10.1186/s12885-018-4155-6

Internet

http://link.springer.com/article/10.1186/s12885-018-4155-6

Similar Items